
Merck & Co., Inc.
MRKHealthcare|Drug Manufacturers - General|US
$146.71
-0.23 (-0.16%)
DCF Value
$180.27
Graham Number
$20.09
Cash / Share
$3.89
Next Earnings Report
Feb 2, 2027
EPS est. $1.78 · Revenue est. $16.29B
Financing Filings (last 12 months)
4
Shelf registrations / offering prospectuses — latest May 20, 2026 (424B5). Possible dilution.
Upcoming Data Readouts (49)
Nov 2026
Est. completion
P1Acute Myeloid Leukemia
Venetoclax and Bomedemstat in Patients With Relapsed/Refractory Acute Myeloid Leukemia
NCT05597306n=18
Dec 2026
Est. completion
Dec 2026
Est. completion
COVID-19
ARMOR-Household: Characterizing Transmission of COVID-19 in Households of SARS-CoV-2 Index Cases
NCT05467917n=374
Dec 2026
Est. completion
P1P2Primary Central Nervous System Lymphoma
Pembrolizumab, Ibrutinib and Rituximab in PCNSL
NCT04421560n=37
Dec 2026
Est. completion
P2Uterine Carcinosarcoma
A Study of Pembrolizumab With Lenvatinib in Women With Advanced Uterine Carcinosarcoma
NCT05147558n=40
Dec 2026
Est. completion
P1Healthy Participants
A Trial to Evaluate the Effect of CD388/MK1406 on the Immunogenicity of Fluzone® HD Vaccine (CD388.SQ.1.08/MK-1406-007)
NCT07300085n=710
Dec 2026
Est. completion
P1Multiple Myeloma in Relapse
Study of HPN217 in Participants With Relapsed/Refractory Multiple Myeloma MK-4002 (MK-4002-001)
NCT04184050n=100
Jan 2027
Est. completion
Jan 2027
Est. completion
P3Urothelial Carcinoma
Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2
NCT05911295n=412
Jan 2027
Est. completion
P2Tumor
Evaluation of the Response and Non-response of Nirogacestat in Desmoid Tumors- Clinical Study
NCT05879146n=40
Feb 2027
Est. completion
P2Renal Cell Carcinoma (RCC)
A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003)
NCT03634540n=118
Mar 2027
Est. completion
P2Pulmonary Disease, Chronic Obstructive, COPD
Effect of Ensifentrine (MK-5884/RPL554) on Sputum Markers of Inflammation in Chronic Obstructive Pulmonary Disease (COPD) (MK-5884-023/RPL554-CO-207)
NCT05270525n=70
Apr 2027
Est. completion
P1P2Carcinoma, Non-Small-Cell Lung
Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
NCT04956640n=540
Apr 2027
Est. completion
P1P2Chronic Lymphocytic Leukemia
Study to Evaluate the Safety and Preliminary Efficacy of Ibrutinib and Pembrolizumab in Patients With Chronic Lymphocytic Leukemia (CLL) or Mantle Cell Lymphoma (MCL)
NCT03153202n=23
Apr 2027
Est. completion
P2Bladder Cancer
Pembrolizumab (MK-3475) and Bacillus Calmette-Guérin (BCG) as First-Line Treatment for High-Risk T1 Non-Muscle-Invasive Bladder Cancer (NMIBC) and High-Grade Non-Muscle-Invasive Upper Tract Urothelial Carcinoma (NMI-UTUC)]
NCT03504163n=45
Apr 2027
Est. completion
P2VHL - Von Hippel-Lindau Syndrome
A Phase 2 Study of Belzutifan (PT2977, MK-6482) for the Treatment of Von Hippel Lindau (VHL) Disease-Associated Renal Cell Carcinoma (RCC) (MK-6482-004)
NCT03401788n=50
Apr 2027
Est. completion
P1P2Advanced Solid Tumor
Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Participants With Advanced Solid Malignant Tumors
NCT04145622n=247
Jun 2027
Est. completion
P3Influenza
A Study to Evaluate the Safety and Efficacy of MK-1406/CD388 for Prevention of Influenza (MK-1406-005/CD388.SQ.3.06)
NCT07159763n=10,000
Jul 2027
Est. completion
P1P2Bladder Cancer
A Clinical Study of MK-3120 in People With Bladder Cancer (MK-3120-003)
NCT07222488n=45
Jul 2027
Est. completion
P2Healthy Participants
A Study of Annual Doses of MK-1406/CD388 in Healthy Adults (MK-1406-006/CD388.SQ.2.07)
NCT07225959n=400
Awaiting Results (26)
Trials past primary completion date but still active — data readout may be imminent.
Oct 2026
P2
IMG-7289 in Patients With Essential Thrombocythemia (ET) or Polycythemia Vera (PV)
NCT04262141Aug 2026
P3
A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001)
NCT06052059May 2026
P2
Pembrolizumab in Combination With R-ICE Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma
NCT05221645Apr 2026
P2
Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)
NCT05270668Feb 2026
P3
A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)
NCT04586231Dec 2025
P1
A Phase 1b Trial to Evaluate Safety of MB097 in Combination With Pembrolizumab in Melanoma Patients
NCT06540391Recent Press Releases
Merck Initiates Phase 3 Study Evaluating Ohtuvayre® (ensifentrine) for the Prevention of COPD Exacerbations in Adult Patients Receiving Standard of Care With a History of Exacerbations
Nov 3, 2026 · Business Wire
Merck to Present New Data from Its Broad Oral HIV Portfolio and Pipeline at HIV Glasgow 2026
Nov 2, 2026 · Business Wire
Lost Money on Merck & Co., Inc. Stock? Glancy Prongay Wolke & Rotter LLP Investigates Possible Securities Fraud After 1.76% Share Price Drop
Oct 30, 2026 · Business Wire
Did You Lose Money on Merck & Co., Inc. Stock? The Law Offices of Howard G.
Oct 30, 2026 · Business Wire
Lost Money on Merck & Co., Inc. Shares? The Law Offices of Frank R.
Oct 29, 2026 · Business Wire
Merck & Co., Inc., Rahway, N.J., USA Announces Third-Quarter 2026 Financial Results; Highlights Multiple Milestones Advancing Broad, Diverse Pipeline
Oct 29, 2026 · Business Wire
Sacituzumab Tirumotecan (Sac-TMT) Reduced the Risk of Death by 32% and the Risk of Disease Progression or Death by 41% Compared to Chemotherapy in Certain Patients With Advanced or Recurrent Endometrial Cancer
Oct 26, 2026 · Business Wire
Merck and Moderna Will Present Results From Landmark Phase 3 INTerpath-001 Trial for Intismeran Autogene Plus KEYTRUDA® (pembrolizumab) at ESMO 2026 Presidential Symposium
Oct 22, 2026 · Business Wire
SEC Filings (69)
Last two years from EDGAR. Insider Form 4s are on the Ownership tab.
| Filed | Form | What it is | Links |
|---|---|---|---|
| Nov 4, 2026 | 10-Q | Quarterly report | DocumentIndex |
| Oct 29, 2026 | 8-K | Material event | DocumentIndex |
| Oct 15, 2026 | 25-NSE | DocumentIndex | |
| Oct 13, 2026 | 8-K | Material event | DocumentIndex |
| Aug 7, 2026 | 10-Q | Quarterly report | DocumentIndex |
| Aug 7, 2026 | 13F-HR | Institutional holdings report | DocumentIndex |
| Aug 4, 2026 | 8-K | Material event | DocumentIndex |
| Jun 24, 2026 | 11-K | DocumentIndex | |
| Jun 24, 2026 | 11-K | DocumentIndex | |
| Jun 24, 2026 | 11-K | DocumentIndex | |
| May 29, 2026 | SD | DocumentIndex | |
| May 28, 2026 | 8-K | Material event | DocumentIndex |
| May 22, 2026 | 8-K | Material event | DocumentIndex |
| May 20, 2026 | 424B5 | Offering prospectus | DocumentIndex |
| May 19, 2026 | FWP | DocumentIndex | |
| May 18, 2026 | 424B5 | Offering prospectus | DocumentIndex |
| May 13, 2026 | 13F-HR | Institutional holdings report | DocumentIndex |
| May 5, 2026 | SC TO-T/A | Tender offer | DocumentIndex |
| May 4, 2026 | 10-Q | Quarterly report | DocumentIndex |
| Apr 30, 2026 | SC 13G | Passive 5%+ stake | DocumentIndex |
| Apr 30, 2026 | 8-K | Material event | DocumentIndex |
| Apr 24, 2026 | SC TO-T/A | Tender offer | DocumentIndex |
| Apr 8, 2026 | ARS | Annual report to holders | DocumentIndex |
| Apr 8, 2026 | DEFA14A | Proxy / shareholder vote | DocumentIndex |
| Apr 8, 2026 | DEF 14A | Proxy / shareholder vote | DocumentIndex |
| Apr 7, 2026 | SC TO-T | Tender offer | DocumentIndex |
| Mar 27, 2026 | SC 13G/A | Passive 5%+ stake | DocumentIndex |
| Feb 24, 2026 | 10-K | Annual report | DocumentIndex |
| Feb 17, 2026 | 13F-HR | Institutional holdings report | DocumentIndex |
| Feb 3, 2026 | 8-K | Material event | DocumentIndex |
| Jan 7, 2026 | SC TO-T/A | Tender offer | DocumentIndex |
| Dec 19, 2025 | SC TO-T/A | Tender offer | DocumentIndex |
| Dec 17, 2025 | SC TO-T/A | Tender offer | DocumentIndex |
| Dec 5, 2025 | SC TO-T | Tender offer | DocumentIndex |
| Dec 4, 2025 | 8-K | Material event | DocumentIndex |
| Dec 3, 2025 | 424B5 | Offering prospectus | DocumentIndex |
| Dec 2, 2025 | FWP | DocumentIndex | |
| Dec 1, 2025 | 424B5 | Offering prospectus | DocumentIndex |
| Nov 12, 2025 | 13F-HR | Institutional holdings report | DocumentIndex |
| Nov 5, 2025 | 10-Q | Quarterly report | DocumentIndex |